WoundGenex
WoundGenex provides revenue cycle management, clinical documentation improvement, credentialing, and deferred-payment wound care product distribution to US wound care, podiatry, vascular, and dermatology providers, with specialty focus on Medicare CTP and skin substitute reimbursement.
- Company typePrivate
- Founded2014
- HeadquartersTampa, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What WoundGenex does
WoundGenex is a privately held, Tampa, Florida-based healthcare services company founded in 2014 that provides revenue cycle management (RCM), clinical documentation improvement (CDI), and credentialing and enrollment services to wound care providers in the United States. The company is built around wound care specialty billing, with a particular focus on Medicare cellular and tissue-based product (CTP) reimbursement, skin substitute billing, LCD compliance, and denial management. Its technology platform is an online client portal that enables electronic insurance verification requests, product inventory tracking, clinical team communication, and electronic CTP logs; there is no public API, SDK, or AI/ML product capability disclosed in the company's own material.
WoundGenex monetizes through multi-year, quote-based enterprise contracts with healthcare facilities across wound care centers, physician practices, hospitals, surgical centers, nursing homes, and mobile wound care providers, with specialty service lines for podiatry, vascular surgery, and dermatology. In addition to professional services revenue, the company distributes advanced wound care products — including MiMedx placental allografts (EPIFIX, EPICORD, EpiEffect, Celera, Epixpress, RegenKit Wound Gel), UltraMIST therapy, and MolecuLight wound imaging devices — through the Premier Graft Program, a deferred-payment model underpinned by an exclusive distribution partnership with MiMedx Group (Nasdaq: MDXG) established in March 2022.
The company has no disclosed outside funding and appears to be founder-owned, with Thomas Smith serving as President and Co-founder and Tom listed as CEO. In September 2025, WoundGenex formalized a strategic alliance with Shoreline Medical Administration to bundle its RCM platform with Medicare clawback protection backed by an A-rated insurance carrier. The company's go-to-market is direct enterprise field sales supplemented by content marketing on wound care reimbursement policy, credentialing best practices, and regulatory updates published through its corporate website.
WoundGenex firmographics
Firmographics- Name
- WoundGenex
- Legal name
- WoundGenex
- Website
- https://woundgenex.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- WoundGenex provides revenue cycle management, clinical documentation improvement, credentialing, and deferred-payment wound care product distribution to US wound care, podiatry, vascular, and dermatology providers, with specialty focus on Medicare CTP and skin substitute reimbursement.
- Ownership category
- akta.pro rank
WoundGenex industry classification
Industry- Product category
- Healthcare Revenue Cycle Management
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Wound Care & Ulcer Management (HLAKACAN)
- akta.pro secondary industries
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Care & Limb Preservation Centers (Post-Acute) (HLADAJAM)
Keywords
Where WoundGenex is headquartered
LocationHeadquarters
- HQ city
- Tampa
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
WoundGenex business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Revenue Cycle Management Services: Full-spectrum RCM solutions including claims processing, insurance verification, accounts receivable management, denial management, and billing optimization for wound care practices
- Clinical Documentation Improvement Services: CDI services focused on accurate and comprehensive clinical documentation to support proper coding, billing, and compliance
- Credentialing & Enrollment Services: Provider enrollment and credentialing management, contract negotiations, and ongoing credential maintenance
- Premier Graft Program: Deferred payment model for wound care grafting products where providers pay only after receiving reimbursement, facilitated through group purchasing power with no upfront cost
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise pricing for healthcare facilities |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
WoundGenex product offering
Product offeringCore offering
WoundGenex provides full-spectrum wound care revenue cycle management (RCM), clinical documentation improvement (CDI), credentialing and enrollment services, and program management for healthcare providers across the United States. The company also distributes advanced wound care products including MiMedx placental allografts (EPIFIX, Epicord, EpiEffect, Celera, Epixpress, RegenKit Wound Gel), UltraMIST therapy, and MolecuLight wound imaging devices, primarily through its Premier Graft Program with a deferred payment model.
Product overview
WoundGenex is a wound care revenue cycle management and practice management solutions company founded in 2014, serving wound care centers, physician practices, nursing homes, and hospitals. The company operates as a distributor of advanced wound care products including MiMedx placental allografts (Epifix, Epicord, EpiEffect, Celera, Epixpress, RegenKit Wound Gel), UltraMIST therapy, and MolecuLight wound imaging devices (MolecuLightDX, MolecuLight i:X). WoundGenex's core offerings include Revenue Cycle Management, Clinical Documentation Improvement, Credentialing & Enrollment, and the Premier Graft Program—a deferred payment model enabling providers to access products with payment due only after reimbursement. The company also provides an online client portal for insurance verification, inventory tracking, and documentation management.
Differentiator
Problem solved
Functional benefit
Products and services
- Revenue Cycle Management (RCM) Full-spectrum Revenue Cycle Management solutions for wound care practices including eligibility verification, claims submission, insurance correspondence, denial management, accounts receivable management, and reimbursement optimization.
- Clinical Documentation Improvement (CDI) Clinical Documentation Improvement services ensuring accurate, comprehensive, and compliant clinical documentation in wound care including assessment, analysis, education, training, and technology integration to support proper coding, billing, and audit readiness.
- Credentialing & Enrollment Provider enrollment and credentialing management services including contract negotiations, ongoing credential maintenance, and ensuring accurate, compliant, and timely submissions to payers.
- Premier Graft Program Deferred payment program providing healthcare providers access to advanced wound care grafting products (MiMedx allografts) with payment due only after reimbursement is realized, leveraging group purchasing power with no upfront cost to providers.
- EPIFIX (distributed product) MiMedx advanced wound care placental allograft product used for treating diabetic foot ulcers and other chronic wounds, covered by 100% of national commercial payors.
- EPICORD (distributed product) MiMedx placental allograft product used for wound care applications.
- EpiEffect (distributed product) Tri-layer human placental allograft that promotes healing in acute and chronic wounds, combining benefits of human placental tissue with practical application advantages.
- CELERA (distributed product) MiMedx advanced wound care product for advanced wound management.
- EPIXPRESS (distributed product) MiMedx wound care placental allograft product for advanced wound management.
- RegenKit Wound Gel (distributed product) Wound care gel product for advanced wound management applications.
- UltraMIST (distributed product) Wound care therapy system used in advanced wound treatment.
- MolecuLightDX (distributed product) Wound imaging device for advanced wound care diagnostics.
- MolecuLight i:X (distributed product) Wound imaging device for wound care visualization and assessment.
Quantifiable outcome
- Reduces claim denials through accurate coding and documentation
- +2 more outcomes
Companies that use WoundGenex
Customer profileNamed customers4 records
Segments6 records
Ideal customer profiles3 records
WoundGenex technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
WoundGenex partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Shoreline Medical AdministrationcoreStrategic alliance to deliver bundled revenue cycle solutions with Clawback Protection Guarantee. Shoreline provides rigorous documentation oversight, LCD compliance expertise, and AI validation tools, while WoundGenex provides industry-leading RCM services. The partnership safeguards providers against costly Medicare clawbacks backed by an A-rated insurance carrier.
- MiMedx Group, Inc.coreExclusive partnership to launch the Premier Graft Program providing MiMedx advanced wound care products (EPIFIX, Epicord, EpiEffect, Celera, Epixpress, RegenKit Wound Gel) through WoundGenex's group purchasing model. Providers access products with no upfront payment until reimbursement is realized.
Scale indicators4 records
Recent moves4 records
Expansion highlights6 records
WoundGenex competitors and assessment
Company assessmentBroad incumbents
- nThrive: nThrive provides end-to-end revenue cycle management, analytics, and consulting to acute-care and specialty providers. Comparable to WoundGenex as a direct RCM competitor with broader scale and a multi-specialty portfolio.
- Waystar: Waystar is a healthcare payments and RCM technology platform serving 1M+ providers. Comparable as a tech-enabled claims and revenue cycle vendor, though more horizontal than WoundGenex's wound-care-specialized offering.
- Parallon: Parallon delivers revenue cycle, credentialing, and workforce solutions to hospitals and physician practices. Comparable as a scaled RCM/credentialing services peer operating across multiple healthcare segments.
- Conifer Health Solutions: Conifer provides revenue cycle management, patient engagement, and value-based care services for hospitals, health systems, and physician practices. Comparable as an enterprise-scale RCM incumbent with broad service breadth.
- Experian Health: Experian Health provides patient access, RCM, and identity-management solutions to hospitals and physician practices. Comparable as a large-scale healthcare revenue cycle technology vendor, broader than wound-care-specialized offerings.
Direct peers
- Wound Care Advantage: Wound Care Advantage offers consulting, program management, and operational support specifically to wound care centers and hyperbaric programs. Closest direct peer given the same wound-care vertical focus on practice optimization and reimbursement.
- Aviacode (now CorroHealth): Aviacode / CorroHealth offers technology-enabled medical coding and CDI services, including specialty-specific coding for wound care, radiology, and other niches. Comparable as a coding and CDI services peer to WoundGenex's specialty documentation business.
- Zotec Partners: Zotec Partners delivers specialized revenue cycle management and billing services for physician practices, including niche medical specialties. Comparable as a specialty-focused RCM/BPO peer competing for specialty-practice billing engagements.
- GeBBS Healthcare Solutions: GeBBS provides medical coding, RCM, and clinical documentation improvement services to health systems and physician groups, including specialty practices. Comparable as a mid-size RCM/CDI/BPO peer serving specialty providers.
Others
- MiMedx Group: MiMedx is WoundGenex's exclusive Premier Graft Program partner, manufacturer of placental allograft skin substitutes (Epifix, Epicord, EpiEffect, Celera, Epixpress). Relevant as the upstream product vendor rather than a direct competitor.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
WoundGenex social profiles
Digital presenceWoundGenex financial estimates
Financial estimateRevenue estimate
Valuation estimate
WoundGenex leadership team
Management profileNumber of profiles
Profiles1 record
WoundGenex funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WoundGenex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WoundGenex
What does WoundGenex do?
WoundGenex provides full-spectrum wound care revenue cycle management (RCM), clinical documentation improvement (CDI), credentialing and enrollment services, and program management for healthcare providers across the United States. The company also distributes advanced wound care products including MiMedx placental allografts (EPIFIX, Epicord, EpiEffect, Celera, Epixpress, RegenKit Wound Gel), UltraMIST therapy, and MolecuLight wound imaging devices, primarily through its Premier Graft Program with a deferred payment model.
Is WoundGenex a public or private company?
WoundGenex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was WoundGenex founded?
WoundGenex was founded in 2014. It employs 251 to 500 people.
Where is WoundGenex based?
WoundGenex is headquartered in Tampa, United States, in the North America region.
How does WoundGenex make money?
Four revenue lines are on record. Revenue Cycle Management Services are the primary driver. The others are clinical Documentation Improvement Services, credentialing & Enrollment Services and premier Graft Program.
Who are WoundGenex's main competitors?
Broad incumbents on record are nThrive, Waystar, Parallon, Conifer Health Solutions and Experian Health. Direct peers are Wound Care Advantage, Aviacode (now CorroHealth), Zotec Partners and GeBBS Healthcare Solutions. MiMedx Group is listed as an others.
Does WoundGenex have an API?
No public API is recorded for WoundGenex.
What industry is WoundGenex in?
WoundGenex's product category is Healthcare Revenue Cycle Management. Its primary akta.pro industry code is HLAKACAN, Wound Care & Ulcer Management, with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its SIC code is 8000.